Literature DB >> 920745

Carbenicillin-gentamicin interaction in acute renal failure.

R T Weibert, W F Keane.   

Abstract

A case is reported in which carbenicillin inactivation of gentamicin resulted in subtherapeutic serum gentamicin levels in a 77-year-old man with acute renal failure. The drugs were administered separately to prevent in vitro inactivation. Carbenicillin inactivation of gentamicin resulted in subtherapeutic serum gentamicin levels (less than 2 microgram/ml) even with unusually large doses of gentamicin (1.8 mg/kg/day). The large dose of carbenicillin (15 g/day) resulted in serum carbenicillin levels more than 500 microgram/ml and an increased rate of gentamicin inactivation. After carbenicillin was discontinued, therapeutic serum gentamicin levels were achieved and maintained with doses of 0.9 - 1.8 mg/kg/day. It is suggested that if the combination of carbenicillin and gentamicin is used in patients with severe renal failure, the dose of carbenicillin should be reduced to prevent rapid inactivation of gentamicin. Further, to assure therapeutic gentamicin levels, serum levels of both drugs should be monitored frequently.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 920745

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  3 in total

1.  Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease.

Authors:  C E Halstenson; C A Hirata; K L Heim-Duthoy; P A Abraham; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  Pattern of systemic antibiotic use and potential drug interactions: Evaluations through a point prevalence study in Ankara University Hospitals.

Authors:  İrem Akdemir Kalkan; Güle Çınar; Aysel Pehlivanlı; Fatih Ürkmez; İzel Ezgi Topaloğlu; Büşra Akyol; Arzu Onay Beşikçi; Alpay Azap; Kemal Osman Memikoğlu
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.